Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Takeda Begins Phase IIb Clinical Trial Of Norovirus Vaccine

XTALKS VITALS NEWS

Vaccine

According to Takeda, an earlier clinical trial of the norovirus vaccine found that the drug was well tolerated among the 98 trial participants, but did not significantly reduce diarrhea or vomiting symptoms.

Share this!

June 22, 2016 | by Sarah Massey, M.Sc.

The only vaccine currently in development to prevent norovirus infection has just entered a Phase IIb clinical trial. The developer of the vaccine – Takeda Pharmaceuticals – has started dosing patients to assess the efficacy of the norovirus vaccine candidate.

Tweet: Takeda Pharmaceuticals is dosing patients with #norovirus vaccine candidate http://ctt.ec/GIkYD+

Norovirus is a highly-infectious intestinal illness which leads to diarrhea and vomiting. Much like other infectious diseases that cause these symptoms, norovirus can cause severe dehydration which has the potential to be fatal.

The Japan-based drugmaker’s intramuscular vaccine – known as TAK-214 – uses virus-like particles to mimic the antigen-coated surface of the norovirus. According to Takeda, an earlier clinical trial of the norovirus vaccine found that the drug was well tolerated among the 98 trial participants, but did not significantly reduce diarrhea or vomiting symptoms.

Norovirus is associated with approximately 20 percent of all cases of diarrheal disease worldwide, according to the Centers for Disease Control and Prevention (CDC). Their estimates suggest that the average person could expect to become ill from a norovirus infection between three and eight times in their lifetime.



As there is no approved drug to treat patients with norovirus, efforts have been focused on preventing transmission of the disease. Norovirus can be acquired from contact with infected individuals and contaminated food and surfaces.

Currently, there is no available vaccine to prevent norovirus infection. “We are excited to be on the frontline of development of a vaccine against norovirus,” said Rajeev Venkayya, president of Takeda Vaccines.

Around 3,400 participants will be enrolled in the Phase IIb clinical trial, according to Takeda. The company expects that the trial will run until August of 2017.


Keywords: Clinical Trials, Norovirus, Vaccine


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.